Opinion|Videos|January 20, 2025
Clinical Scenario: Patient Receiving First-Line ESA Without a Marked Response: What Do You Do Next?
Panelists discuss how to approach patients who show inadequate response to initial erythropoiesis-stimulating agent (ESA) therapy, including assessment strategies and potential next steps in treatment modification.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Heath Skinner, MD, PhD, discussed which new radiation oncology service lines community practices can implement, how leadership decides, and what launches require.
Advertisement
Advertisement
Trending on CancerNetwork
1
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
2
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
3
CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial
4
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
5